GlassScriptPhysician profile
Joyce Choi Peji
NPI 1538152160
$7,044.22
in general payments reported to CMS, 2019-2025
36 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $522 · 2021: $1,778 · 2022: $1,338 · 2023: $920 · 2024: $601 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203 · Education: $56.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.29 |
| Education | $56.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,440.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,094.64 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $836.25 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $412.43 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $208.87 | 2019-2023 | Dificid |
| Pfizer INC. | $206.97 | 2019-2025 | |
| Medtronic, INC. | $198.67 | 2022-2024 | Interstim |
| Boston Scientific Corporation | $161.71 | 2021-2025 | Cre Pro, Compliance Endokit, Orcapod |
| Allergan, INC. | $161.63 | 2019-2020 | |
| Janssen Biotech, INC. | $140.32 | 2019-2025 | Stelara, Tremfya |
| Celltrion USA INC. | $126.07 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Ironwood Pharmaceuticals, INC | $107.79 | 2019-2023 | Linzess |
| Lilly USA, LLC | $104.67 | 2024-2025 | Omvoh |
| Vivus LLC | $93.98 | 2021-2022 | |
| Daiichi Sankyo INC. | $91.84 | 2020-2025 | Injectafer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $79.33 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $55.54 | 2022 | |
| Braintree Laboratories, INC. | $54.96 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $54.95 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $48.64 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $41.67 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $34.41 | 2024 | |
| Ambu INC. | $34.28 | 2020-2021 | |
| Novo Nordisk INC | $31.53 | 2025 | Wegovy |
| Qol Medical, LLC | $27.62 | 2024 | Sucraid |
| Amgen INC. | $23.49 | 2023 | Avsola, Amjevita |
| E.R. Squibb & Sons, L.L.C. | $22.45 | 2021 | |
| Ardelyx, INC. | $20.05 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $19.39 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $19.34 | 2025 | Voquezna |
| Axonics, INC. | $17.37 | 2020 | |
| Gilead Sciences, INC. | $16.42 | 2023 | |
| Endo Pharmaceuticals INC. | $15.74 | 2020 | |
| Ucb, INC. | $14.50 | 2020 | |
| Alfasigma USA, INC. | $14.02 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Peji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.